Health Economics Spending: Prioritizing HEOR Activities at Global Groups

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Pharmaceutical companies under increasing pressure to provide a full product story to key payers.  As such, heath economics spending is also growing.  Rising stakeholder expectations demand that HEOR groups generate more pharmacoeconomic and outcomes data for each emerging drug or medical device.  To provide these data, global HEOR teams allocate a large percentage of their annual funding to cultivating  information for government and private payers worldwide. Continue reading


The Big Three: How Payers, Patients, and Physicians are Driving the Future of Comparative Effectiveness Research

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

Over the past few months at Cutting Edge Information we have been working on collecting data for a new report on comparative effectiveness research and a common theme throughout the research has been the need for stakeholder engagement that goes beyond the traditional payer-centric model.  Working with patients and physicians — along with pharmacies, regulators, and other stakeholders — is not a new phenomenon for manufacturers.  However, the emphasis on getting this engagement right is growing as companies respond to the changing healthcare marketplace in the US and in Europe. Continue reading





Majority of Global Health Economics and Outcomes Research Teams Begin Working with Developing Products in Phase 2

David Richardson, pharmaceutical commercialization and launch expert
By David Richardson,
Director of Research

In our most recent study examining health economics teams, 64% of responding global health economics and outcomes research teams revealed that they begin working with developing products during Phase 2 — though most desired an even earlier start.  HEOR directors and managers want early involvement to help them understand payers’ hot-button issues as early as possible. Continue reading


What Are Patients Saying? Using PRO Instruments to Impact Product Marketing Claims

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

As the pharmaceutical industry transitions to more patient-centric marketing, companies are looking to patient-reported outcomes to inform product labels.  Often, clinical or PRO teams will implement PRO instruments during Phase 2 or Phase 3 trials to collect end-user feedback.  This feedback is particularly useful as companies look to prove a product’s comparative effectiveness and product label claim approval.  While PRO endpoints are becoming increasingly popular, companies still find gaining approval for these findings is a complex process. Continue reading



HEOR Data Needs to be Tailored to Match Market Needs

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

When health economics groups are working on developing HEOR data, they need to keep in mind the different gaps that the research may be needed to fill.  Depending on the market, whether right at launch or years afterwards, payers may see product’s position significantly strengthened by the appropriate HEOR data.  Developing the right information can require customization based on geography or based on the competitive landscape. Continue reading